Skip to content
Taxonomy
Novartis Secures $1.3B Deal for CMT Treatment CKD-510
Novartis is making significant strides in the field of Charcot-Marie-Tooth Read More
Therapeutic Inactivation of CMT2 Disease Alleles with CRISPR
New technologies in gene editing such as CRISPR/Cas9 present a Read More
CMTA Announces Participation in Seed Extension Round for Armatus Bio for Novel CMT1A Gene Therapy
First Investment from CMTA’s New Venture Philanthropy Arm The Charcot-Marie-Tooth Read More
CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E
The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28 Read More
Muscular Dystrophy Association and Charcot-Marie-Tooth Association Announce Collaborative Non-Viral Gene Therapy Research Grant
New York, NY – September 12, 2023 — The Muscular Read More
CMTA Hails Novartis Acquisition of DTx Pharma And Its CMT1A Therapeutic Program
The Charcot-Marie-Tooth Association July 17 hailed the news that global Read More
Development of Treatments for CMT2D
Professor Robert Burgess and his team at The Jackson Laboratory Read More
CMTA Updates List of Neurotoxic Meds Potentially More Hazardous to CMT Patients
The Charcot-Marie-Tooth Association (CMTA) announced the results of a review Read More
Development of Advanced Research Diagnostic Capabilities for the CMT Community
CMT is a genetic disease caused by distinct changes in Read More
Studying Neurodegeneration in CMT1X Mouse Model
In people with CMT1X cell-to-cell communication within the peripheral nervous Read More
